1. Protein Tyrosine Kinase/RTK Anti-infection Autophagy
  2. Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy
  3. Imatinib

Imatinib  (Synonyms: STI571; CGP-57148B)

Cat. No.: HY-15463 Purity: 99.95%
SDS COA Handling Instructions Technical Support

Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.

For research use only. We do not sell to patients.

Imatinib Chemical Structure

Imatinib Chemical Structure

CAS No. : 152459-95-5

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
200 mg In-stock
500 mg In-stock
1 g In-stock
5 g In-stock
10 g   Get quote  
50 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 95 publication(s) in Google Scholar

Other Forms of Imatinib:

Top Publications Citing Use of Products

88 Publications Citing Use of MCE Imatinib

WB
Proliferation Assay
IHC

    Imatinib purchased from MedChemExpress. Usage Cited in: Cell Chem Biol. 2018 Aug 16;25(8):996-1005.e4.  [Abstract]

    Negligible increases in caspase-3 activity or PARP-1 cleavage is observed in PC-9 GR NSCLC cells treated with DMSO, single agent PAC-1 (5 mM), or Osimertinib (Osi). In cells treated with PAC-1+Osimertinib, dramatic increases in caspase-3 activity is observed as early as 36 hr post treatment.

    Imatinib purchased from MedChemExpress. Usage Cited in: Oncotarget. 2018 Apr 24;9(31):22158-22183.  [Abstract]

    Primary tumors are dissected at the end of experiment and subjected to immunohistochemistry. Representative images of primary tumor sections stained with anti-PCNA (proliferation), anti-cleaved caspase 3 (apoptosis), and anti-CD31 (angiogenesis).

    Imatinib purchased from MedChemExpress. Usage Cited in: PLoS One. 2017 Jun 1;12(6):e0178619.  [Abstract]

    The protein expression of PDGF-A, PDGF-B, PDGF-C, and PDGF-D in hearts from mice treated with vehicle, Imatinib (IMA), ISO, IMA+ISO for one week is tested by Western blot.

    Imatinib purchased from MedChemExpress. Usage Cited in: Med Sci Monit. 2017 Aug 6;23:3808-3816.  [Abstract]

    The kinase activity of c-Kit is enhanced in an animal model of cardiac fibrosis. The lysates of heart tissues from a mice model treated with vehicle, Imatinib (IMA), ISO, or Imatinib + ISO for one week are analyzed for phosphorylation level of p-c-Kit (Tyr719) and total protein level of c-Kit. The western blotting results from one mouse in each group and the statistical analysis of the western blotting bands are shown.

    Imatinib purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Nov 15;8(67):111110-111118.  [Abstract]

    In cell EC50 determination of CHMFL-KIT-031 with parental Colo320DM (KIT wt) and KIT V559D overexpressed Colo320DM cells.

    Imatinib purchased from MedChemExpress. Usage Cited in: J Med Chem. 2016 Sep 22;59(18):8456-72.  [Abstract]

    Effect of compounds 1 (Imatinib), 2 (Sunitinib), and 35 on cKIT mediated signaling pathways in GIST-T1 and GIST-5R cancer cell lines.

    Imatinib purchased from MedChemExpress. Usage Cited in: J Bioenerg Biomembr. 2012 Feb;44(1):155-61.  [Abstract]

    Differences in sensitivity of PDR-mutants to 3-BP, Imatinib methanesulfonate, Daunorubicin and Rhodamine 6 G. Minimal medium (YNB) with sucrose.

    View All PDGFR Isoform Specific Products:

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively[1][2][3][4]. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV[5].

    IC50 & Target

    BCR/ABL, v-Abl, PDGFR, c-kit[1][2][4]

    Cellular Effect
    Cell Line Type Value Description References
    786-0 GI50
    16 μM
    Compound: Imatinib
    Growth inhibition of human 786-0 cells measured after 48 hrs by SRB assay
    Growth inhibition of human 786-0 cells measured after 48 hrs by SRB assay
    [PMID: 32942186]
    A10 IC50
    162 nM
    Compound: 1
    Inhibition of PDGFR-beta driven proliferation of rat A10 cells after 68 hrs in presence of rat recombinant PDGF-BB by cell titer-glo luminescence assay
    Inhibition of PDGFR-beta driven proliferation of rat A10 cells after 68 hrs in presence of rat recombinant PDGF-BB by cell titer-glo luminescence assay
    [PMID: 27502700]
    A2780 IC50
    4.8 x 10-5 M
    Compound: 1
    Cytotoxicity against human A2780 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human A2780 cells after 72 hrs by alamar-blue cell viability assay
    [PMID: 19301902]
    A2780 IC50
    8.9 μM
    Compound: Imatinib
    Antiproliferative activity against human A2780 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A2780 cells after 72 hrs by MTT assay
    [PMID: 29684708]
    A-431 IC50
    3.1 x 10-5 M
    Compound: 1
    Cytotoxicity against human A431 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human A431 cells after 72 hrs by alamar-blue cell viability assay
    [PMID: 19301902]
    A498 GI50
    21.98 μM
    Compound: Imatinib
    Growth inhibition of human A498 cells measured after 48 hrs by SRB assay
    Growth inhibition of human A498 cells measured after 48 hrs by SRB assay
    [PMID: 32942186]
    A549 IC50
    > 25 μM
    Compound: Imatinib
    Antiproliferative activity against human A549 cells after 72 hrs by CellTiter 96 aqueous one solution assay
    Antiproliferative activity against human A549 cells after 72 hrs by CellTiter 96 aqueous one solution assay
    [PMID: 30562697]
    A549 IC50
    15.5 μM
    Compound: 1
    Cytotoxicity against human A549 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human A549 cells after 72 hrs by alamar-blue cell viability assay
    [PMID: 19301902]
    A549 GI50
    24.49 μM
    Compound: Imatinib
    Growth inhibition of human A549 cells measured after 48 hrs by SRB assay
    Growth inhibition of human A549 cells measured after 48 hrs by SRB assay
    [PMID: 32942186]
    A549 IC50
    4.56 μM
    Compound: Imatinib
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    [PMID: 28525838]
    ACHN GI50
    25.23 μM
    Compound: Imatinib
    Growth inhibition of human ACHN cells measured after 48 hrs by SRB assay
    Growth inhibition of human ACHN cells measured after 48 hrs by SRB assay
    [PMID: 32942186]
    ASPC1 IC50
    4.4 x 10-5 M
    Compound: 1
    Cytotoxicity against human AsPC1 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human AsPC1 cells after 72 hrs by alamar-blue cell viability assay
    [PMID: 19301902]
    BaF3 IC50
    > 1 μM
    Compound: Imatinib
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay
    [PMID: 26195136]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Growth inhibition of mouse BAF3 cells measured after 72 hrs by CCK8 assay
    Growth inhibition of mouse BAF3 cells measured after 72 hrs by CCK8 assay
    [PMID: 31250638]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of TEL fused c-KIT T670I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of TEL fused c-KIT T670I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    [PMID: 31046271]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of TEL fused c-KIT T670I/V559D double mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of TEL fused c-KIT T670I/V559D double mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    [PMID: 31046271]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of TEL fused c-KIT D816V mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of TEL fused c-KIT D816V mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    [PMID: 31046271]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Antiproliferative activity in mouse BAF3 cells after 72 hrs by CCK8 assay
    Antiproliferative activity in mouse BAF3 cells after 72 hrs by CCK8 assay
    [PMID: 30317026]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of BCR/ABL T315I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of BCR/ABL T315I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    [PMID: 30317026]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of wild type C-terminal FLAG-tagged human TEL fused ABL T315I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of wild type C-terminal FLAG-tagged human TEL fused ABL T315I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    [PMID: 30317026]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of BCR/ABL Y253F mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of BCR/ABL Y253F mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    [PMID: 30317026]
    BaF3 IC50
    > 10 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    [PMID: 23301703]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Cytotoxicity mouse BA/F3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay
    Cytotoxicity mouse BA/F3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay
    [PMID: 27545040]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells after 72 hrs by CellTiter-Glo or CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells after 72 hrs by CellTiter-Glo or CCK-8 assay
    [PMID: 29544149]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Growth inhibition of mouse BAF3 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Growth inhibition of mouse BAF3 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of Tel-fused BLK (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused BLK (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of Tel-fused DDR1 (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused DDR1 (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of BCR-fused DDR2 (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of BCR-fused DDR2 (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of Tel-fused LCK (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused LCK (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of Tel-fused VEGFR2 (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused VEGFR2 (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of BCR/ABL p210 fusion protein T315I mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of BCR/ABL p210 fusion protein T315I mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of BCR/ABL p210 fusion protein Y253H mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of BCR/ABL p210 fusion protein Y253H mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of Tel-fused c-KIT T670I/V559D double mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused c-KIT T670I/V559D double mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of Tel-fused c-KIT D816V mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused c-KIT D816V mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of Tel-fused cKIT T670I mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    Inhibition of Tel-fused cKIT T670I mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    [PMID: 27077705]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of Tel-fused cKIT D816V mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    Inhibition of Tel-fused cKIT D816V mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    [PMID: 27077705]
    BaF3 GI50
    > 10 μM
    Compound: Imatinib
    Inhibition of BCR/ABL p210-Y253F mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-Y253F mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    [PMID: 26789553]
    BaF3 GI50
    > 10 μM
    Compound: Imatinib
    Inhibition of BCR/ABL p210-T315I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-T315I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    [PMID: 26789553]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Cytotoxicity in mouse parental BA/F3 cells incubated for 72 hrs by MTS assay
    Cytotoxicity in mouse parental BA/F3 cells incubated for 72 hrs by MTS assay
    [PMID: 30204441]
    BaF3 IC50
    > 10 μM
    Compound: imatinib
    Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells assessed as proliferation after 48 hrs by MTT assay
    Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells assessed as proliferation after 48 hrs by MTT assay
    [PMID: 16415863]
    BaF3 IC50
    > 10 μM
    Compound: imatinib
    Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells expressing FIt3-ITD kinase assessed as proliferation after 48 hrs by MTT assay
    Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells expressing FIt3-ITD kinase assessed as proliferation after 48 hrs by MTT assay
    [PMID: 16415863]
    BaF3 IC50
    > 10 μM
    Compound: imatinib
    Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells expressing TPR-MET kinase assessed as proliferation after 48 hrs by MTT assay
    Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells expressing TPR-MET kinase assessed as proliferation after 48 hrs by MTT assay
    [PMID: 16415863]
    BaF3 IC50
    > 10 μM
    Compound: imatinib
    Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells expressing Tel-JAK1 kinase assessed as proliferation after 48 hrs by MTT assay
    Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells expressing Tel-JAK1 kinase assessed as proliferation after 48 hrs by MTT assay
    [PMID: 16415863]
    BaF3 IC50
    > 10 μM
    Compound: imatinib
    Cytotoxicity against mouse BA/F3 cells after 48 hrs by XTT assay
    Cytotoxicity against mouse BA/F3 cells after 48 hrs by XTT assay
    [PMID: 23600806]
    BaF3 IC50
    > 100 nM
    Compound: Imatinib
    Cytotoxicity against mouse BAF3 cells expressing native BCR-ABL assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity against mouse BAF3 cells expressing native BCR-ABL assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    [PMID: 34011155]
    BaF3 IC50
    > 100 nM
    Compound: Imatinib
    Cytotoxicity against mouse BAF3 cells expressing BCR-ABL T315I mutant assessed as inhibition of cell growth measured after 48 hrs by trypan blue assay
    Cytotoxicity against mouse BAF3 cells expressing BCR-ABL T315I mutant assessed as inhibition of cell growth measured after 48 hrs by trypan blue assay
    [PMID: 34011155]
    BaF3 IC50
    > 100 μM
    Compound: Imatinib
    Inhibition of NPM/ALK L256T mutant kinase activity in BaF3 cells by radioenzymatic assay
    Inhibition of NPM/ALK L256T mutant kinase activity in BaF3 cells by radioenzymatic assay
    [PMID: 16970400]
    BaF3 EC50
    > 1000 nM
    Compound: Imatinib
    Inhibition of human BCR-ABL T315I mutant expressed in mouse BAF3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Inhibition of human BCR-ABL T315I mutant expressed in mouse BAF3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    [PMID: 27010810]
    BaF3 IC50
    > 30 μM
    Compound: Imatinib
    Inhibition of wild type NPM/ALK autophosphorylation activity in BaF3 cells by antiphosphotyrosine immunoblotting assay
    Inhibition of wild type NPM/ALK autophosphorylation activity in BaF3 cells by antiphosphotyrosine immunoblotting assay
    [PMID: 16970400]
    BaF3 IC50
    > 30 μM
    Compound: Imatinib
    Inhibition of NPM/ALK L256T mutant autophosphorylation activity in BaF3 cells by antiphosphotyrosine immunoblotting assay
    Inhibition of NPM/ALK L256T mutant autophosphorylation activity in BaF3 cells by antiphosphotyrosine immunoblotting assay
    [PMID: 16970400]
    BaF3 IC50
    > 30 μM
    Compound: Imatinib
    Inhibition of wild type NPM/ALK kinase activity in BaF3 cells by radioenzymatic assay
    Inhibition of wild type NPM/ALK kinase activity in BaF3 cells by radioenzymatic assay
    [PMID: 16970400]
    BaF3 GI50
    0.001 μM
    Compound: 1
    Inhibition of TEL fused c-KIT V559G mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of TEL fused c-KIT V559G mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    [PMID: 31046271]
    BaF3 GI50
    0.005 μM
    Compound: 1
    Inhibition of TEL fused c-KIT V559A mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of TEL fused c-KIT V559A mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    [PMID: 31046271]
    BaF3 GI50
    0.019 μM
    Compound: 1
    Inhibition of Tel-fused PDGFR-beta (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused PDGFR-beta (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    BaF3 IC50
    0.027 μM
    Compound: imatinib
    Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells expressing Tel-PDGFRbeta kinase assessed as proliferation after 48 hrs by MTT assay
    Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells expressing Tel-PDGFRbeta kinase assessed as proliferation after 48 hrs by MTT assay
    [PMID: 16415863]
    BaF3 GI50
    0.034 μM
    Compound: 1
    Inhibition of Tel-fused PDGFR-alpha (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused PDGFR-alpha (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    BaF3 GI50
    0.039 μM
    Compound: 1
    Inhibition of TEL fused c-KIT V559D mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of TEL fused c-KIT V559D mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    [PMID: 31046271]
    BaF3 GI50
    0.039 μM
    Compound: 1
    Inhibition of Tel-fused c-KIT V559D mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused c-KIT V559D mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    BaF3 GI50
    0.039 μM
    Compound: 1
    Inhibition of Tel-fused cKIT V559D mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    Inhibition of Tel-fused cKIT V559D mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    [PMID: 27077705]
    BaF3 IC50
    0.092 μM
    Compound: imatinib
    Cytotoxicity against mouse BA/F3 cells transfected with wild type Bcr-Abl after 48 hrs by XTT assay
    Cytotoxicity against mouse BA/F3 cells transfected with wild type Bcr-Abl after 48 hrs by XTT assay
    [PMID: 23600806]
    BaF3 GI50
    0.1 μM
    Compound: 1
    Inhibition of Tel-fused cKIT L567P mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    Inhibition of Tel-fused cKIT L567P mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    [PMID: 27077705]
    BaF3 GI50
    0.102 μM
    Compound: 1
    Inhibition of Tel-fused c-KIT L576P mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused c-KIT L576P mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    BaF3 GI50
    0.11 μM
    Compound: 1
    Inhibition of Tel-fused CSF1R (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused CSF1R (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    BaF3 GI50
    0.115 μM
    Compound: 1
    Inhibition of TEL fused c-KIT L576P mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of TEL fused c-KIT L576P mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    [PMID: 31046271]
    BaF3 IC50
    0.19 μM
    Compound: imatinib
    Antiproliferative activity against mouse BA/F3 cells transfected with p210 Bcr-abl assessed as proliferation after 48 hrs by MTT assay
    Antiproliferative activity against mouse BA/F3 cells transfected with p210 Bcr-abl assessed as proliferation after 48 hrs by MTT assay
    [PMID: 16415863]
    BaF3 IC50
    0.23 μM
    Compound: Imatinib
    Antiproliferative activity against mouse BaF3 cells expressing wild type Bcr-Abl assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent assay
    Antiproliferative activity against mouse BaF3 cells expressing wild type Bcr-Abl assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent assay
    [PMID: 35561654]
    BaF3 IC50
    0.24 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL M351T mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL M351T mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    [PMID: 23301703]
    BaF3 GI50
    0.26 μM
    Compound: 1
    Inhibition of wild type C-terminal FLAG-tagged human TEL fused ABL (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of wild type C-terminal FLAG-tagged human TEL fused ABL (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    [PMID: 30317026]
    BaF3 GI50
    0.267 μM
    Compound: 1
    Inhibition of TEL fused c-KIT D820E mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of TEL fused c-KIT D820E mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    [PMID: 31046271]
    BaF3 GI50
    0.27 μM
    Compound: 1
    Inhibition of human BCR/ABL p210 fusion protein expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of human BCR/ABL p210 fusion protein expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    BaF3 GI50
    0.29 μM
    Compound: 1
    Inhibition of wild type BCR/ABL (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of wild type BCR/ABL (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    [PMID: 30317026]
    BaF3 GI50
    0.364 μM
    Compound: 1
    Inhibition of wild type TEL fused c-KIT (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of wild type TEL fused c-KIT (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    [PMID: 31046271]
    BaF3 GI50
    0.37 μM
    Compound: 1
    Inhibition of Tel-fused c-KIT (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused c-KIT (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    BaF3 GI50
    0.38 μM
    Compound: Imatinib
    Inhibition of BCR/ABL p210 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    [PMID: 26789553]
    BaF3 GI50
    0.4 μM
    Compound: 1
    Inhibition of Tel-fused cKIT (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    Inhibition of Tel-fused cKIT (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    [PMID: 27077705]
    BaF3 GI50
    0.406 μM
    Compound: 1
    Inhibition of TEL fused c-KIT A829P mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of TEL fused c-KIT A829P mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    [PMID: 31046271]
    BaF3 IC50
    0.5 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing wild type BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing wild type BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay
    [PMID: 23301703]
    BaF3 GI50
    0.5 μM
    Compound: Imatinib
    Inhibition of TEL-LCK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of TEL-LCK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    [PMID: 26789553]
    BaF3 IC50
    0.59 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E359V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E359V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    [PMID: 23301703]
    BaF3 GI50
    0.625 μM
    Compound: 1
    Inhibition of BCR/ABL p210 fusion protein M356T mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of BCR/ABL p210 fusion protein M356T mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    BaF3 GI50
    0.625 μM
    Compound: Imatinib
    Inhibition of BCR/ABL p210-M351T mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-M351T mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    [PMID: 26789553]
    BaF3 GI50
    0.65 μM
    Compound: 1
    Inhibition of BCR/ABL V299L mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of BCR/ABL V299L mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    [PMID: 30317026]
    BaF3 GI50
    0.659 μM
    Compound: Imatinib
    Inhibition of BCR/ABL p210-Q252H mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-Q252H mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    [PMID: 26789553]
    BaF3 GI50
    0.823 μM
    Compound: 1
    Inhibition of TEL fused c-KIT D816H mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of TEL fused c-KIT D816H mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    [PMID: 31046271]
    BaF3 GI50
    0.85 μM
    Compound: 1
    Inhibition of BCR/ABL M351T mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of BCR/ABL M351T mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    [PMID: 30317026]
    BaF3 GI50
    0.85 μM
    Compound: 1
    Inhibition of BCR/ABL p210 fusion protein F317I mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of BCR/ABL p210 fusion protein F317I mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    BaF3 GI50
    0.855 μM
    Compound: Imatinib
    Inhibition of BCR/ABL p210-F317I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-F317I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    [PMID: 26789553]
    BaF3 GI50
    0.95 μM
    Compound: 1
    Inhibition of BCR/ABL F317I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of BCR/ABL F317I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    [PMID: 30317026]
    BaF3 IC50
    1 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F486S mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F486S mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    [PMID: 23301703]
    BaF3 GI50
    1.17 μM
    Compound: 1
    Inhibition of BCR/ABL Q252H mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of BCR/ABL Q252H mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    [PMID: 30317026]
    BaF3 GI50
    1.29 μM
    Compound: 1
    Inhibition of TEL fused c-KIT N822K mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of TEL fused c-KIT N822K mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    [PMID: 31046271]
    BaF3 GI50
    1.29 μM
    Compound: 1
    Inhibition of Tel-fused c-KIT N822K mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused c-KIT N822K mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    BaF3 GI50
    1.29 μM
    Compound: 1
    Inhibition of Tel-fused cKIT N822K mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    Inhibition of Tel-fused cKIT N822K mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    [PMID: 27077705]
    BaF3 GI50
    1.57 μM
    Compound: 1
    Inhibition of TEL fused c-KIT V654A/V559D double mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of TEL fused c-KIT V654A/V559D double mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    [PMID: 31046271]
    BaF3 IC50
    1.6 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E355G mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E355G mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    [PMID: 23301703]
    BaF3 GI50
    1.69 μM
    Compound: Imatinib
    Inhibition of BCR/ABL p210-H369P mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-H369P mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    [PMID: 26789553]
    BaF3 GI50
    1.79 μM
    Compound: 1
    Inhibition of BCR/ABL p210 fusion protein H369P mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of BCR/ABL p210 fusion protein H369P mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    BaF3 GI50
    1.93 μM
    Compound: Imatinib
    Inhibition of BCR/ABL p210-E255K mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-E255K mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    [PMID: 26789553]
    BaF3 IC50
    10 μM
    Compound: Imatinib
    Antiproliferative activity against mouse BaF3 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent assay
    Antiproliferative activity against mouse BaF3 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent assay
    [PMID: 35561654]
    BaF3 IC50
    11.1 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL H396R mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL H396R mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    [PMID: 23301703]
    BaF3 IC50
    110 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl H396P mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl H396P mutant after 72 hrs by CCK-8 assay
    [PMID: 23088644]
    BaF3 IC50
    12.2 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL T315I mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL T315I mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    [PMID: 23301703]
    BaF3 IC50
    12.2 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL L248V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL L248V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    [PMID: 23301703]
    BaF3 IC50
    12.5 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Y253H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Y253H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    [PMID: 23301703]
    BaF3 IC50
    129 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl M244V mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl M244V mutant after 72 hrs by CCK-8 assay
    [PMID: 23088644]
    BaF3 IC50
    13.5 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CCK-8 assay
    [PMID: 23301703]
    BaF3 IC50
    1444 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Y253F mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Y253F mutant after 72 hrs by CCK-8 assay
    [PMID: 23088644]
    BaF3 IC50
    14500 nM
    Compound: Imatinib
    Growth inhibition of mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 48 hrs by MTT assay
    Growth inhibition of mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 48 hrs by MTT assay
    [PMID: 26562217]
    BaF3 IC50
    17083 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Y253H mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Y253H mutant after 72 hrs by CCK-8 assay
    [PMID: 23088644]
    BaF3 IC50
    1834 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing wild type Bcr-Abl after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing wild type Bcr-Abl after 72 hrs by CCK-8 assay
    [PMID: 23088644]
    BaF3 IC50
    18520 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells after 72 hrs by CCK-8 assay
    [PMID: 23088644]
    BaF3 IC50
    1863 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl G250E mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl G250E mutant after 72 hrs by CCK-8 assay
    [PMID: 23088644]
    BaF3 IC50
    190 nM
    Compound: imatinib
    Antiproliferation activity against mouse BA/F3 cells expressing Bcr-abl assessed as cell viability after 48 hrs by MTT assay
    Antiproliferation activity against mouse BA/F3 cells expressing Bcr-abl assessed as cell viability after 48 hrs by MTT assay
    [PMID: 16415863]
    BaF3 GI50
    2.1 μM
    Compound: Imatinib
    Inhibition of TEL-SRC (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of TEL-SRC (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    [PMID: 26789553]
    BaF3 GI50
    2.16 μM
    Compound: 1
    Inhibition of BCR/ABL p210 fusion protein F317L mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of BCR/ABL p210 fusion protein F317L mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    BaF3 GI50
    2.169 μM
    Compound: Imatinib
    Inhibition of BCR/ABL p210-F317L mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-F317L mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    [PMID: 26789553]
    BaF3 GI50
    2.24 μM
    Compound: 1
    Inhibition of BCR/ABL F317L mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of BCR/ABL F317L mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    [PMID: 30317026]
    BaF3 GI50
    2.3 μM
    Compound: 1
    Inhibition of TEL fused c-KIT V654A mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of TEL fused c-KIT V654A mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    [PMID: 31046271]
    BaF3 GI50
    2.49 μM
    Compound: 1
    Inhibition of Tel-fused c-KIT V654A mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused c-KIT V654A mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    BaF3 GI50
    2.49 μM
    Compound: 1
    Inhibition of Tel-fused cKIT V654A mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    Inhibition of Tel-fused cKIT V654A mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    [PMID: 27077705]
    BaF3 IC50
    221 nM
    Compound: 1, Glivec, Gleevec
    Inhibition of human BCR-ABL1 autophosphorylation expressed in mouse BA/F3 cells by ELISA
    Inhibition of human BCR-ABL1 autophosphorylation expressed in mouse BA/F3 cells by ELISA
    [PMID: 23611771]
    BaF3 IC50
    2377 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl H396R mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl H396R mutant after 72 hrs by CCK-8 assay
    [PMID: 23088644]
    BaF3 IC50
    2547 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl F486S mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl F486S mutant after 72 hrs by CCK-8 assay
    [PMID: 23088644]
    BaF3 IC50
    2951 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E255K mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E255K mutant after 72 hrs by CCK-8 assay
    [PMID: 23088644]
    BaF3 GI50
    3 μM
    Compound: 1
    Inhibition of Tel-fused c-KIT V559D/V654A double mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused c-KIT V559D/V654A double mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    BaF3 GI50
    3 μM
    Compound: 1
    Inhibition of Tel-fused cKIT V559D/V654A double mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    Inhibition of Tel-fused cKIT V559D/V654A double mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    [PMID: 27077705]
    BaF3 GI50
    3 μM
    Compound: Imatinib
    Inhibition of TEL-DDR1 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of TEL-DDR1 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    [PMID: 26789553]
    BaF3 IC50
    3.3 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F317L mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F317L mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    [PMID: 23301703]
    BaF3 IC50
    3.6 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Q252H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Q252H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    [PMID: 23301703]
    BaF3 GI50
    3.75 μM
    Compound: 1
    Inhibition of BCR/ABL H369P mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of BCR/ABL H369P mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    [PMID: 30317026]
    BaF3 IC50
    3005 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay
    [PMID: 23088644]
    BaF3 IC50
    339 nM
    Compound: imatinib
    Antiproliferation activity against mouse BA/F3 cells expressing Bcr-abl A337N mutant assessed as cell viability after 48 hrs by MTT assay
    Antiproliferation activity against mouse BA/F3 cells expressing Bcr-abl A337N mutant assessed as cell viability after 48 hrs by MTT assay
    [PMID: 16415863]
    BaF3 EC50
    34 nM
    Compound: Imatinib
    Inhibition of human wild type BCR-ABL expressed in mouse BAF3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Inhibition of human wild type BCR-ABL expressed in mouse BAF3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    [PMID: 27010810]
    BaF3 IC50
    362 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E355G mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E355G mutant after 72 hrs by CCK-8 assay
    [PMID: 23088644]
    BaF3 IC50
    3763 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Q252H mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Q252H mutant after 72 hrs by CCK-8 assay
    [PMID: 23088644]
    BaF3 IC50
    393 nM
    Compound: imatinib
    Antiproliferative activity against mouse BA/F3 cells expressing NPM-abl assessed as cell viability at 5 to 10 uM after 48 hrs by MTT assay
    Antiproliferative activity against mouse BA/F3 cells expressing NPM-abl assessed as cell viability at 5 to 10 uM after 48 hrs by MTT assay
    [PMID: 16415863]
    BaF3 GI50
    4.1 μM
    Compound: Imatinib
    Inhibition of TEL-BLK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of TEL-BLK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    [PMID: 26789553]
    BaF3 GI50
    4.686 μM
    Compound: 1
    Antiproliferative activity against mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay
    Antiproliferative activity against mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay
    [PMID: 28541695]
    BaF3 IC50
    4.79 μM
    Compound: imatinib
    Cytotoxicity against mouse BA/F3 cells transfected with Bcr-Abl T315I mutant after 48 hrs by XTT assay
    Cytotoxicity against mouse BA/F3 cells transfected with Bcr-Abl T315I mutant after 48 hrs by XTT assay
    [PMID: 23600806]
    BaF3 IC50
    424 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl M351T mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl M351T mutant after 72 hrs by CCK-8 assay
    [PMID: 23088644]
    BaF3 IC50
    5.2 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL G250E mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL G250E mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    [PMID: 23301703]
    BaF3 IC50
    5.6 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255K mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255K mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    [PMID: 23301703]
    BaF3 IC50
    55 nM
    Compound: imatinib
    Antiproliferative activity against mouse BA/F3 cells expressing Tel-SH2-KD assessed as cell viability at 5 to 10 uM after 48 hrs by MTT assay
    Antiproliferative activity against mouse BA/F3 cells expressing Tel-SH2-KD assessed as cell viability at 5 to 10 uM after 48 hrs by MTT assay
    [PMID: 16415863]
    BaF3 GI50
    6.67 μM
    Compound: 1
    Inhibition of Tel-fused c-KIT T670I mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused c-KIT T670I mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    BaF3 GI50
    6.67 μM
    Compound: 1
    Inhibition of Tel-fused cKIT T670I/V559D double mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    Inhibition of Tel-fused cKIT T670I/V559D double mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    [PMID: 27077705]
    BaF3 GI50
    6.7 μM
    Compound: Imatinib
    Antiproliferative activity against mouse BA/F3 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    [PMID: 26789553]
    BaF3 IC50
    678 nM
    Compound: 1, Glivec, Gleevec
    Inhibition of human BCR-ABL1 expressed in mouse BA/F3 cells assessed as cell growth inhibition by ATP-depletion assay
    Inhibition of human BCR-ABL1 expressed in mouse BA/F3 cells assessed as cell growth inhibition by ATP-depletion assay
    [PMID: 23611771]
    BaF3 IC50
    7.1 μM
    Compound: Imatinib
    Antiproliferative activity against murine BaF3 cells expressing wild type NPM/ALK by [3H]thymidine uptake assay
    Antiproliferative activity against murine BaF3 cells expressing wild type NPM/ALK by [3H]thymidine uptake assay
    [PMID: 16970400]
    BaF3 GI50
    7.7 μM
    Compound: Imatinib
    Inhibition of TEL-DDR2 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of TEL-DDR2 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    [PMID: 26789553]
    BaF3 IC50
    8615 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E255V mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E255V mutant after 72 hrs by CCK-8 assay
    [PMID: 23088644]
    BaF3 IC50
    88 nM
    Compound: imatinib
    Antiproliferative activity against mouse BA/F3 cells expressing Tel-SH3-SH2-KD assessed as cell viability at 5 to 10 uM after 48 hrs by MTT assay
    Antiproliferative activity against mouse BA/F3 cells expressing Tel-SH3-SH2-KD assessed as cell viability at 5 to 10 uM after 48 hrs by MTT assay
    [PMID: 16415863]
    BaF3 IC50
    89 nM
    Compound: Imatinib
    Growth inhibition of mouse BA/F3 cells expressing wild-type Bcr-Abl after 48 hrs by MTT assay
    Growth inhibition of mouse BA/F3 cells expressing wild-type Bcr-Abl after 48 hrs by MTT assay
    [PMID: 26562217]
    BaF3 IC50
    9.1 μM
    Compound: Imatinib
    Antiproliferative activity against murine BaF3 cells expressing NPM/ALK L256T mutant by [3H]thymidine uptake assay
    Antiproliferative activity against murine BaF3 cells expressing NPM/ALK L256T mutant by [3H]thymidine uptake assay
    [PMID: 16970400]
    BaF3 IC50
    9.2 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Y253F mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Y253F mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    [PMID: 23301703]
    BaF3 IC50
    9.5 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F317V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F317V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    [PMID: 23301703]
    BaF3 GI50
    9.7 μM
    Compound: Imatinib
    Inhibition of TEL-HCK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of TEL-HCK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    [PMID: 26789553]
    BaF3 IC50
    960 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl F359V mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl F359V mutant after 72 hrs by CCK-8 assay
    [PMID: 23088644]
    BaF3 IC50
    962 nM
    Compound: imatinib
    Antiproliferation activity against mouse BA/F3 cells expressing Bcr-abl A334l mutant assessed as cell viability after 48 hrs by MTT assay
    Antiproliferation activity against mouse BA/F3 cells expressing Bcr-abl A334l mutant assessed as cell viability after 48 hrs by MTT assay
    [PMID: 16415863]
    BJ GI50
    > 40 μM
    Compound: Imatinib
    Cytotoxicity against human BJ cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis
    Cytotoxicity against human BJ cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis
    [PMID: 31514019]
    BT-549 GI50
    16.11 μM
    Compound: Imatinib
    Growth inhibition of human BT-549 cells measured after 48 hrs by SRB assay
    Growth inhibition of human BT-549 cells measured after 48 hrs by SRB assay
    [PMID: 32942186]
    BV-173 GI50
    0.1 μM
    Compound: Imatinib
    Antiproliferative activity against human BV173 cells after 48 hrs by Cell-Titer-Glo luminescent cell viability assay
    Antiproliferative activity against human BV173 cells after 48 hrs by Cell-Titer-Glo luminescent cell viability assay
    [PMID: 27011159]
    BV-173 IC50
    20 μM
    Compound: Imatinib
    In vitro antiproliferative activity against human BV173 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    In vitro antiproliferative activity against human BV173 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    [PMID: 24681986]
    CAKI-1 GI50
    33.96 μM
    Compound: Imatinib
    Growth inhibition of human CAKI-1 cells measured after 48 hrs by SRB assay
    Growth inhibition of human CAKI-1 cells measured after 48 hrs by SRB assay
    [PMID: 32942186]
    CAL-27 IC50
    2.2 x 10-5 M
    Compound: 1
    Cytotoxicity against human CAL27 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human CAL27 cells after 72 hrs by alamar-blue cell viability assay
    [PMID: 19301902]
    CCRF-CEM GI50
    16.98 μM
    Compound: Imatinib
    Antiproliferative activity against human CCRF-CEM cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human CCRF-CEM cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    [PMID: 32961435]
    CCRF-CEM GI50
    16.98 μM
    Compound: Imatinib
    Growth inhibition of human CCRF-CEM cells measured after 48 hrs by SRB assay
    Growth inhibition of human CCRF-CEM cells measured after 48 hrs by SRB assay
    [PMID: 32942186]
    CCRF-CEM GI50
    35.809 μM
    Compound: Imatinib
    Cytotoxicity against human CEM cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis
    Cytotoxicity against human CEM cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis
    [PMID: 31514019]
    CCRF-CEM IC50
    36 μM
    Compound: 1
    Cytotoxicity against human CCRF-CEM cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human CCRF-CEM cells after 72 hrs by alamar-blue cell viability assay
    [PMID: 19301902]
    CCRF-CEM IC50
    45 μM
    Compound: Imatinib
    In vitro antiproliferative activity against human CCRF-CEM cells assessed as decrease in cell viability after 24 hrs by MTT assay
    In vitro antiproliferative activity against human CCRF-CEM cells assessed as decrease in cell viability after 24 hrs by MTT assay
    [PMID: 24681986]
    CCRF-CEM/VCR-1000 IC50
    3.7 x 10-5 M
    Compound: 1
    Cytotoxicity against vincristine-resistant human CCRF-CEM/VCR1000 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against vincristine-resistant human CCRF-CEM/VCR1000 cells after 72 hrs by alamar-blue cell viability assay
    [PMID: 19301902]
    CHO GI50
    > 10 μM
    Compound: 1
    Antiproliferative activity in CHO cells after 72 hrs by CCK8 assay
    Antiproliferative activity in CHO cells after 72 hrs by CCK8 assay
    [PMID: 30317026]
    CHO GI50
    > 10 μM
    Compound: 1
    Antiproliferative activity against CHO cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay
    Antiproliferative activity against CHO cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay
    [PMID: 28541695]
    CHO GI50
    > 10 μM
    Compound: 1
    Antiproliferative activity against CHO cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Antiproliferative activity against CHO cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    CHO GI50
    > 10 μM
    Compound: 1
    Antiproliferative activity against CHO cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    Antiproliferative activity against CHO cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    [PMID: 27077705]
    COLO 205 GI50
    17.62 μM
    Compound: Imatinib
    Growth inhibition of human COLO 205 cells measured after 48 hrs by SRB assay
    Growth inhibition of human COLO 205 cells measured after 48 hrs by SRB assay
    [PMID: 32942186]
    DU-145 GI50
    18.79 μM
    Compound: Imatinib
    Growth inhibition of human DU-145 cells measured after 48 hrs by SRB assay
    Growth inhibition of human DU-145 cells measured after 48 hrs by SRB assay
    [PMID: 32942186]
    EKVX GI50
    26.18 μM
    Compound: Imatinib
    Growth inhibition of human EKVX cells measured after 48 hrs by SRB assay
    Growth inhibition of human EKVX cells measured after 48 hrs by SRB assay
    [PMID: 32942186]
    EM-2 GI50
    0.26 μM
    Compound: Imatinib
    Antiproliferative activity against human EM2 cells after 48 hrs by Cell-Titer-Glo luminescent cell viability assay
    Antiproliferative activity against human EM2 cells after 48 hrs by Cell-Titer-Glo luminescent cell viability assay
    [PMID: 27011159]
    EOL1 GI50
    < 0.0005 μM
    Compound: Imatinib
    Cytotoxicity against FIP1L1-PDGFRA positive human EOL-1 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis
    Cytotoxicity against FIP1L1-PDGFRA positive human EOL-1 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis
    [PMID: 31514019]
    EOL1 GI50
    < 0.001 μM
    Compound: 1
    Antiproliferative activity against human EOL-1 cells after 72 hrs by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against human EOL-1 cells after 72 hrs by CellTiter-Glo or CCK-8 assay
    [PMID: 29544149]
    EOL1 IC50
    0.0002 μM
    Compound: 1
    Cytotoxicity against human EOL-1 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human EOL-1 cells after 72 hrs by alamar-blue cell viability assay
    [PMID: 19301902]
    GIST430 GI50
    1100 nM
    Compound: 1
    Cytotoxicity against human GIST430 cells harboring KIT V654A mutant assessed as cell growth inhibition after 72 hrs by CellTiterGlo assay
    Cytotoxicity against human GIST430 cells harboring KIT V654A mutant assessed as cell growth inhibition after 72 hrs by CellTiterGlo assay
    [PMID: 28991465]
    GIST430 GI50
    625 nM
    Compound: 1
    Antiproliferative activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant assessed as cell growth inhibition after 120 hrs by methylene blue staining
    Antiproliferative activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant assessed as cell growth inhibition after 120 hrs by methylene blue staining
    [PMID: 31721578]
    GIST430 GI50
    929 nM
    Compound: Imatinib
    Antiproliferative activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant assessed as reduction in cell viability by MTS assay
    Antiproliferative activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant assessed as reduction in cell viability by MTS assay
    [PMID: 30968693]
    GIST430 GI50
    929 nM
    Compound: Imatinib
    Antiproliferative activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant assessed as reduction in cell viability by methylene blue staining based ass
    Antiproliferative activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant assessed as reduction in cell viability by methylene blue staining based ass
    [PMID: 30968693]
    GIST48 IC50
    18.7 μM
    Compound: imatinib
    Cytotoxicity against human GIST48 cells assessed as effect on cell viability after 3 to 6 days by luciferase based luminescence assay
    Cytotoxicity against human GIST48 cells assessed as effect on cell viability after 3 to 6 days by luciferase based luminescence assay
    [PMID: 19469547]
    GIST48 GI50
    625 nM
    Compound: Imatinib
    Antiproliferative activity against human GIST48 cells harboring c-KIT exon 11 homozygous primary missense V560D mutant and exon 17 heterozygous secondary D820A mutant assessed as reduction in cell viability by MTS assay
    Antiproliferative activity against human GIST48 cells harboring c-KIT exon 11 homozygous primary missense V560D mutant and exon 17 heterozygous secondary D820A mutant assessed as reduction in cell viability by MTS assay
    [PMID: 30968693]
    GIST48 GI50
    625 nM
    Compound: Imatinib
    Antiproliferative activity against human GIST48 cells harboring c-KIT exon 11 homozygous primary missense V560D mutant and exon 17 heterozygous secondary D820A mutant assessed as reduction in cell viability by methylene blue staining based assay
    Antiproliferative activity against human GIST48 cells harboring c-KIT exon 11 homozygous primary missense V560D mutant and exon 17 heterozygous secondary D820A mutant assessed as reduction in cell viability by methylene blue staining based assay
    [PMID: 30968693]
    GIST48 GI50
    929 nM
    Compound: 1
    Antiproliferative activity against human GIST48 cells harboring c-KIT exon 11 homozygous primary missense V560D mutant and exon 17 heterozygous secondary D820A mutant assessed as cell growth inhibition after 120 hrs by methylene blue staining based assay
    Antiproliferative activity against human GIST48 cells harboring c-KIT exon 11 homozygous primary missense V560D mutant and exon 17 heterozygous secondary D820A mutant assessed as cell growth inhibition after 120 hrs by methylene blue staining based assay
    [PMID: 31721578]
    GIST882 GI50
    0.014 μM
    Compound: 1
    Antiproliferative activity against human GIST882 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Antiproliferative activity against human GIST882 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    GIST882 GI50
    0.014 μM
    Compound: 1
    Antiproliferative activity against cKIT dependent human GIST882 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    Antiproliferative activity against cKIT dependent human GIST882 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    [PMID: 27077705]
    GIST882 GI50
    0.02 μM
    Compound: 1
    Antiproliferative activity against human GIST882 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay
    Antiproliferative activity against human GIST882 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay
    [PMID: 28541695]
    GIST882 GI50
    0.058 μM
    Compound: 1
    Antiproliferative activity against human GIST882 cells harboring c-KIT K642E mutant incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human GIST882 cells harboring c-KIT K642E mutant incubated for 72 hrs by CCK8 assay
    [PMID: 31046271]
    GIST882 IC50
    1.7 μM
    Compound: imatinib
    Antiproliferative activity against human GIST882 cells after 96 hrs by SRB assay
    Antiproliferative activity against human GIST882 cells after 96 hrs by SRB assay
    [PMID: 19469547]
    GIST882 GI50
    195 nM
    Compound: Imatinib
    Antiproliferative activity against human GIST882 cells harboring c-KIT exon 13 homozygous primary K642E mutant assessed as reduction in cell viability by MTS assay
    Antiproliferative activity against human GIST882 cells harboring c-KIT exon 13 homozygous primary K642E mutant assessed as reduction in cell viability by MTS assay
    [PMID: 30968693]
    GIST882 GI50
    195 nM
    Compound: 1
    Antiproliferative activity against human GIST882 cells harboring c-KIT exon 13 homozygous primary K642E mutant assessed as cell growth inhibition after 144 hrs by methylene blue staining based assay
    Antiproliferative activity against human GIST882 cells harboring c-KIT exon 13 homozygous primary K642E mutant assessed as cell growth inhibition after 144 hrs by methylene blue staining based assay
    [PMID: 31721578]
    GIST882 GI50
    195 nM
    Compound: Imatinib
    Antiproliferative activity against human GIST882 cells harboring c-KIT exon 13 homozygous primary K642E mutant assessed as reduction in cell viability by methylene blue staining based assay
    Antiproliferative activity against human GIST882 cells harboring c-KIT exon 13 homozygous primary K642E mutant assessed as reduction in cell viability by methylene blue staining based assay
    [PMID: 30968693]
    GISTT1 GI50
    > 10 μM
    Compound: 1
    Inhibition of c-KIT 560 to 578 deletion/T670I mutant in human GISTT1 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of c-KIT 560 to 578 deletion/T670I mutant in human GISTT1 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    [PMID: 31250638]
    GISTT1 GI50
    > 10 μM
    Compound: 1
    Antiproliferative activity against human GISTT1 cells harboring c-KIT 560 to 578 deletion/T670I double mutant incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human GISTT1 cells harboring c-KIT 560 to 578 deletion/T670I double mutant incubated for 72 hrs by CCK8 assay
    [PMID: 31046271]
    GISTT1 GI50
    0.003 μM
    Compound: 1
    Antiproliferative activity against human GISTT1 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay
    Antiproliferative activity against human GISTT1 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay
    [PMID: 28541695]
    GISTT1 GI50
    0.008 μM
    Compound: 1
    Antiproliferative activity against human GISTT1 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Antiproliferative activity against human GISTT1 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    GISTT1 GI50
    0.008 μM
    Compound: 1
    Antiproliferative activity against cKIT dependent human GISTT1 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    Antiproliferative activity against cKIT dependent human GISTT1 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    [PMID: 27077705]
    GISTT1 GI50
    0.015 μM
    Compound: 1
    Inhibition of c-KIT 560 to 578 deletion mutant in human GISTT1 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of c-KIT 560 to 578 deletion mutant in human GISTT1 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    [PMID: 31250638]
    GISTT1 GI50
    0.026 μM
    Compound: 1
    Antiproliferative activity against human GISTT1 cells harboring c-KIT 560 to 578 deletion mutant incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human GISTT1 cells harboring c-KIT 560 to 578 deletion mutant incubated for 72 hrs by CCK8 assay
    [PMID: 31046271]
    GISTT1 GI50
    40 nM
    Compound: 1
    Cytotoxicity against human GISTT1 cells assessed as cell growth inhibition after 72 hrs by CellTiterGlo assay
    Cytotoxicity against human GISTT1 cells assessed as cell growth inhibition after 72 hrs by CellTiterGlo assay
    [PMID: 28991465]
    GISTT1 GI50
    40 nM
    Compound: 1
    Antiproliferative activity against human GISTT1 cells harboring heterozygous deletion mutation at C-kit exon 11 assessed as cell growth inhibition after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay
    Antiproliferative activity against human GISTT1 cells harboring heterozygous deletion mutation at C-kit exon 11 assessed as cell growth inhibition after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay
    [PMID: 31721578]
    HCC 2998 GI50
    21.23 μM
    Compound: Imatinib
    Growth inhibition of human HCC 2998 cells measured after 48 hrs by SRB assay
    Growth inhibition of human HCC 2998 cells measured after 48 hrs by SRB assay
    [PMID: 32942186]
    HCC827 GI50
    > 40 μM
    Compound: Imatinib
    Cytotoxicity against human HCC827 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis
    Cytotoxicity against human HCC827 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis
    [PMID: 31514019]
    HCT-116 IC50
    1 x 10-5 M
    Compound: 1
    Cytotoxicity against human HCT116 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human HCT116 cells after 72 hrs by alamar-blue cell viability assay
    [PMID: 19301902]
    HCT-116 GI50
    12.59 μM
    Compound: Imatinib
    Growth inhibition of human HCT-116 cells measured after 48 hrs by SRB assay
    Growth inhibition of human HCT-116 cells measured after 48 hrs by SRB assay
    [PMID: 32942186]
    HCT-116 IC50
    19.66 μM
    Compound: Imatinib
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    [PMID: 29684708]
    HCT-116 IC50
    34.3 μM
    Compound: Imatinib
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    [PMID: 33129590]
    HCT-116 IC50
    44.55 μM
    Compound: Imatinib
    Antiproliferative activity against p53+/+ human HCT116 cells after 72 hrs by CellTiter 96 aqueous one solution assay
    Antiproliferative activity against p53+/+ human HCT116 cells after 72 hrs by CellTiter 96 aqueous one solution assay
    [PMID: 30562697]
    HCT-116 IC50
    51.21 μM
    Compound: Imatinib
    Antiproliferative activity against p53-/- human HCT116 cells after 72 hrs by CellTiter 96 aqueous one solution assay
    Antiproliferative activity against p53-/- human HCT116 cells after 72 hrs by CellTiter 96 aqueous one solution assay
    [PMID: 30562697]
    HCT-15 GI50
    19.95 μM
    Compound: Imatinib
    Growth inhibition of human HCT-15 cells measured after 48 hrs by SRB assay
    Growth inhibition of human HCT-15 cells measured after 48 hrs by SRB assay
    [PMID: 32942186]
    HCT-15 IC50
    2.5 x 10-5 M
    Compound: 1
    Cytotoxicity against human HCT15 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human HCT15 cells after 72 hrs by alamar-blue cell viability assay
    [PMID: 19301902]
    HEC-1-A IC50
    1.9 x 10-5 M
    Compound: 1
    Cytotoxicity against human Hec1A cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human Hec1A cells after 72 hrs by alamar-blue cell viability assay
    [PMID: 19301902]
    HEK293 IC50
    > 10 μM
    Compound: STI571
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability measured after 48 hrs by alamar blue assay
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability measured after 48 hrs by alamar blue assay
    [PMID: 35944901]
    HEK293 IC50
    0.05 μM
    Compound: imatinib
    Inhibition of human MATE1-mediated [14]-metformin uptake expressed in HEK293 cells after 1.5 mins by scintillation counting analysis
    Inhibition of human MATE1-mediated [14]-metformin uptake expressed in HEK293 cells after 1.5 mins by scintillation counting analysis
    [PMID: 23241029]
    HEK293 IC50
    0.35 μM
    Compound: imatinib
    Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells up to 500 uM after 1.5 mins by fluorescence assay
    Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells up to 500 uM after 1.5 mins by fluorescence assay
    [PMID: 23241029]
    HEK293 IC50
    0.35 μM
    Compound: imatinib
    Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
    Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
    [PMID: 23241029]
    HEK293 IC50
    107 μM
    Compound: imatinib
    Inhibition of human OCT1-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay
    Inhibition of human OCT1-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay
    [PMID: 23241029]
    HEK293 IC50
    141 nM
    Compound: gleevec, ST1571
    Inhibition of autophosphorylation of DDR2 expressed in HEK293 cells by ELISA
    Inhibition of autophosphorylation of DDR2 expressed in HEK293 cells by ELISA
    [PMID: 20817538]
    HEK293 IC50
    2.9 μM
    Compound: imatinib
    Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
    Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
    [PMID: 23241029]
    HEK293 IC50
    25.5 μM
    Compound: imatinib
    Inhibition of human OCT3-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay
    Inhibition of human OCT3-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay
    [PMID: 23241029]
    HEK293 IC50
    291 nM
    Compound: gleevec, ST1571
    Inhibition of autophosphorylation of CSF1R expressed in HEK293 cells by ELISA
    Inhibition of autophosphorylation of CSF1R expressed in HEK293 cells by ELISA
    [PMID: 20817538]
    HEK293 IC50
    4.2 μM
    Compound: imatinib
    Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay
    Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay
    [PMID: 23241029]
    HEK293 IC50
    43 nM
    Compound: gleevec, ST1571
    Inhibition of autophosphorylation of DDR1 expressed in HEK293 cells by ELISA
    Inhibition of autophosphorylation of DDR1 expressed in HEK293 cells by ELISA
    [PMID: 20817538]
    HEK-293T CC50
    27.54 μM
    Compound: Imatinib
    Cytotoxicity against human 293T cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    Cytotoxicity against human 293T cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    [PMID: 28029512]
    HEL GI50
    5.3 μM
    Compound: Imatinib
    Antiproliferative activity against human HEL cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against human HEL cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    [PMID: 26789553]
    HeLa IC50
    18.65 μM
    Compound: 1
    Cytotoxicity against human HeLa cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human HeLa cells after 72 hrs by alamar-blue cell viability assay
    [PMID: 19301902]
    HeLa CC50
    38.8 μg/mL
    Compound: imatinib
    Cytotoxicity against human HeLa cells after 72 hrs by methylene blue staining
    Cytotoxicity against human HeLa cells after 72 hrs by methylene blue staining
    [PMID: 20153202]
    HepG2 IC50
    > 25 μM
    Compound: Imatinib
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 26707846]
    HepG2 IC50
    10 μM
    Compound: Imatinib
    Antiproliferative activity against human HepG2 cells after 24 to 96 hrs by MTS assay
    Antiproliferative activity against human HepG2 cells after 24 to 96 hrs by MTS assay
    [PMID: 23932071]
    HGC-27 IC50
    2.4 μM
    Compound: Imatinib
    Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay
    Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay
    [PMID: 29724653]
    HGC-27 IC50
    2.4 μM
    Compound: imatinib
    Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay
    Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay
    [PMID: 19469547]
    HGC-27 IC50
    3.8 μM
    Compound: Imatinib
    Cytotoxicity against HGC27 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against HGC27 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 24900584]
    HL-60 GI50
    > 10 μM
    Compound: 1
    Antiproliferative activity in human HL60 cells after 72 hrs by CCK8 assay
    Antiproliferative activity in human HL60 cells after 72 hrs by CCK8 assay
    [PMID: 30317026]
    HL-60 GI50
    > 10 μM
    Compound: 1
    Antiproliferative activity against human HL60 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Antiproliferative activity against human HL60 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    HL-60 GI50
    > 10 μM
    Compound: 1
    Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    [PMID: 27077705]
    HL-60 IC50
    > 10 μM
    Compound: imatinib
    Antiproliferative activity against human HL60 Bcr-abl negative cells assessed as cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human HL60 Bcr-abl negative cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 16415863]
    HL-60 IC50
    0.03 μM
    Compound: Imatinib
    Antiproliferative activity against human HL60 cells assessed as inhibition of cell survival after 72 hrs by MTT assay
    Antiproliferative activity against human HL60 cells assessed as inhibition of cell survival after 72 hrs by MTT assay
    [PMID: 26850004]
    HL-60 IC50
    28.54 μM
    Compound: Imatinib
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay
    [PMID: 36242991]
    HL-60 IC50
    55 μM
    Compound: Imatinib
    In vitro antiproliferative activity against human HL60 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    In vitro antiproliferative activity against human HL60 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    [PMID: 24681986]
    HL-60(TB) GI50
    13.49 μM
    Compound: Imatinib
    Antiproliferative activity against human HL-60(TB) cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human HL-60(TB) cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    [PMID: 32961435]
    HL-60(TB) GI50
    13.49 μM
    Compound: Imatinib
    Growth inhibition of human HL-60(TB) cells measured after 48 hrs by SRB assay
    Growth inhibition of human HL-60(TB) cells measured after 48 hrs by SRB assay
    [PMID: 32942186]
    HOP-62 GI50
    21.53 μM
    Compound: Imatinib
    Growth inhibition of human HOP-62 cells measured after 48 hrs by SRB assay
    Growth inhibition of human HOP-62 cells measured after 48 hrs by SRB assay
    [PMID: 32942186]
    HOP-92 GI50
    13.34 μM
    Compound: Imatinib
    Growth inhibition of human HOP-92 cells measured after 48 hrs by SRB assay
    Growth inhibition of human HOP-92 cells measured after 48 hrs by SRB assay
    [PMID: 32942186]
    HOS-TE85 IC50
    20.5 μM
    Compound: Imatinib
    Antiproliferative activity against human MNNG/HOS cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MNNG/HOS cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 35239349]
    Hs-578T GI50
    14.59 μM
    Compound: Imatinib
    Growth inhibition of human Hs-578T cells measured after 48 hrs by SRB assay
    Growth inhibition of human Hs-578T cells measured after 48 hrs by SRB assay
    [PMID: 32942186]
    HT-29 IC50
    0.06 μM
    Compound: Imatinib
    Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay
    Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay
    [PMID: 29724653]
    HT-29 IC50
    0.06 μM
    Compound: imatinib
    Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay
    Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay
    [PMID: 19469547]
    HT-29 GI50
    3.97 μM
    Compound: Imatinib
    Growth inhibition of human HT-29 cells measured after 48 hrs by SRB assay
    Growth inhibition of human HT-29 cells measured after 48 hrs by SRB assay
    [PMID: 32942186]
    HUVEC GI50
    10.9 μg/mL
    Compound: imatinib
    Antiproliferative activity against HUVEC after 72 hrs by resazurin dye reduction assay
    Antiproliferative activity against HUVEC after 72 hrs by resazurin dye reduction assay
    [PMID: 20153202]
    IGROV-1 GI50
    21.18 μM
    Compound: Imatinib
    Growth inhibition of human IGROV-1 cells measured after 48 hrs by SRB assay
    Growth inhibition of human IGROV-1 cells measured after 48 hrs by SRB assay
    [PMID: 32942186]
    Jurkat IC50
    > 10 μM
    Compound: imatinib
    Antiproliferative activity against human Jurkat Bcr-abl negative cells assessed as proliferation after 48 hrs by MTT assay
    Antiproliferative activity against human Jurkat Bcr-abl negative cells assessed as proliferation after 48 hrs by MTT assay
    [PMID: 16415863]
    Jurkat IC50
    > 1000 nM
    Compound: Imatinib
    Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    [PMID: 34011155]
    K562 GI50
    > 10 μM
    Compound: STI571
    Growth inhibition of human K562 cells expressing BCR-ABL T315I mutant measured after 48 hrs by alamarblue assay
    Growth inhibition of human K562 cells expressing BCR-ABL T315I mutant measured after 48 hrs by alamarblue assay
    [PMID: 35944901]
    K562 GI50
    0.02 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    [PMID: 32961435]
    K562 GI50
    0.02 μM
    Compound: Imatinib
    Growth inhibition of human K562 cells measured after 48 hrs by SRB assay
    Growth inhibition of human K562 cells measured after 48 hrs by SRB assay
    [PMID: 32942186]
    K562 IC50
    0.049 μM
    Compound: 1
    Cytotoxicity against human K562 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human K562 cells after 72 hrs by alamar-blue cell viability assay
    [PMID: 19301902]
    K562 GI50
    0.1 ng/mL
    Compound: imatinib
    Antiproliferative activity against human K562 cells after 72 hrs by resazurin dye reduction assay
    Antiproliferative activity against human K562 cells after 72 hrs by resazurin dye reduction assay
    [PMID: 20153202]
    K562 IC50
    0.1 μM
    Compound: Imatinib
    Cytotoxicity against human K562 cells after 24 hrs by MTT assay
    Cytotoxicity against human K562 cells after 24 hrs by MTT assay
    [PMID: 22632935]
    K562 IC50
    0.109 μM
    Compound: imatinib
    Antiproliferative activity against human K562 expressing Bcr-abl assessed as proliferation after 48 hrs by MTT assay
    Antiproliferative activity against human K562 expressing Bcr-abl assessed as proliferation after 48 hrs by MTT assay
    [PMID: 16415863]
    K562 GI50
    0.12 μM
    Compound: 1
    Antiproliferative activity against BCR-ABL dependent human K562 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    Antiproliferative activity against BCR-ABL dependent human K562 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    [PMID: 27077705]
    K562 IC50
    0.135 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human K562 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay
    [PMID: 36242991]
    K562 GI50
    0.14 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against human K562 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    [PMID: 26789553]
    K562 IC50
    0.14 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells assessed as inhibition of cell viability incubated for 72 hrs by real time live-cell imaging technique
    Antiproliferative activity against human K562 cells assessed as inhibition of cell viability incubated for 72 hrs by real time live-cell imaging technique
    [PMID: 31097376]
    K562 GI50
    0.147 μM
    Compound: 1
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay
    [PMID: 28541695]
    K562 IC50
    0.15 nM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    [PMID: 30605831]
    K562 IC50
    0.18 μM
    Compound: gleevec
    Cytotoxicity against K562 cells by MTT assay
    Cytotoxicity against K562 cells by MTT assay
    [PMID: 17572088]
    K562 GI50
    0.2 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells after 48 hrs by Cell-Titer-Glo luminescent cell viability assay
    Antiproliferative activity against human K562 cells after 48 hrs by Cell-Titer-Glo luminescent cell viability assay
    [PMID: 27011159]
    K562 IC50
    0.22 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells after 48 hrs by trypan blue dye exclusion assay
    Antiproliferative activity against human K562 cells after 48 hrs by trypan blue dye exclusion assay
    [PMID: 26629859]
    K562 GI50
    0.25 μM
    Compound: 1
    Antiproliferative activity in human K562 cells after 72 hrs by CCK8 assay
    Antiproliferative activity in human K562 cells after 72 hrs by CCK8 assay
    [PMID: 30317026]
    K562 GI50
    0.267 μM
    Compound: 1
    Antiproliferative activity against human K562 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Antiproliferative activity against human K562 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    [PMID: 27966954]
    K562 IC50
    0.28 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells expressing wild type Bcr-Abl after 72 hrs by CCK-8 assay
    Antiproliferative activity against human K562 cells expressing wild type Bcr-Abl after 72 hrs by CCK-8 assay
    [PMID: 26195136]
    K562 IC50
    0.38 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells assessed as inhibition of cell survival after 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells assessed as inhibition of cell survival after 72 hrs by MTT assay
    [PMID: 26850004]
    K562 GI50
    0.39 μM
    Compound: 1, Gleevec
    Cytotoxicity against human K562 cells after 72 hrs by MTS assay
    Cytotoxicity against human K562 cells after 72 hrs by MTS assay
    [PMID: 22932313]
    K562 IC50
    0.4 μM
    Compound: STI-571 imatinib
    Inhibitory activity against human K562 cells growth using MTT assay
    Inhibitory activity against human K562 cells growth using MTT assay
    [PMID: 14552760]
    K562 IC50
    0.47 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    [PMID: 25778766]
    K562 IC50
    0.47 μM
    Compound: Imatinib
    Cytotoxicity against human K562 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as growth inhibition after 48 hrs by MTT assay
    [PMID: 23735826]
    K562 IC50
    0.5 μM
    Compound: imatinib
    Cytotoxicity against human K562 cells after 72 hrs using Calcein AM by fluorescence assay
    Cytotoxicity against human K562 cells after 72 hrs using Calcein AM by fluorescence assay
    [PMID: 25757603]
    K562 IC50
    0.5 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    [PMID: 23932071]
    K562 IC50
    0.5 μM
    Compound: Imatinib
    Cytotoxicity against human K562 cells after 72 hrs by calcein-AM assay
    Cytotoxicity against human K562 cells after 72 hrs by calcein-AM assay
    [PMID: 23981532]
    K562 IC50
    0.51 μM
    Compound: Imatinib
    Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by MTT assay
    [PMID: 26814890]
    K562 IC50
    0.53 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    [PMID: 28525838]
    K562 IC50
    0.53 μM
    Compound: Imatinib
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    [PMID: 26707846]
    K562 GI50
    0.563 μM
    Compound: STI571
    Growth inhibition of human K562 cells measured after 48 hrs by alamarblue assay
    Growth inhibition of human K562 cells measured after 48 hrs by alamarblue assay
    [PMID: 35944901]
    K562 IC50
    0.58 μM
    Compound: Imatinib
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    [PMID: 21295380]
    K562 IC50
    0.61 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells by MTT assay
    Antiproliferative activity against human K562 cells by MTT assay
    [PMID: 33132117]
    K562 GI50
    0.73 μM
    Compound: Imatinib
    Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis
    Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis
    [PMID: 31514019]
    K562 IC50
    0.73 μM
    Compound: Imatinib
    Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by fluorescence microplate reader method
    Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by fluorescence microplate reader method
    [PMID: 26741853]
    K562 IC50
    0.75 μM
    Compound: Imatinib
    Inhibition of BCR/ABL p210 autophosphorylation in human K562 cells after 2 hrs by Western blot analysis
    Inhibition of BCR/ABL p210 autophosphorylation in human K562 cells after 2 hrs by Western blot analysis
    [PMID: 20188579]
    K562 GI50
    0.8 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    [PMID: 32961435]
    K562 IC50
    1 μM
    Compound: IM
    Cytotoxicity against imatinib-sensitive human K562 cells assessed as decrease in cell viability after 24 hrs by XTT assay
    Cytotoxicity against imatinib-sensitive human K562 cells assessed as decrease in cell viability after 24 hrs by XTT assay
    [PMID: 30261468]
    K562 IC50
    1.1 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    [PMID: 35561654]
    K562 IC50
    1.1 μM
    Compound: Imatinib
    Cytotoxicity in drug sensitive human K562 cells assessed as reduction cell viability incubated for 48 hrs by XTT assay
    Cytotoxicity in drug sensitive human K562 cells assessed as reduction cell viability incubated for 48 hrs by XTT assay
    [PMID: 29655981]
    K562 IC50
    1.16 μM
    Compound: STI571
    Cytotoxicity against human K562 cells expressing Bcr-Abl assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells expressing Bcr-Abl assessed as growth inhibition after 48 hrs by MTT assay
    [PMID: 26451772]
    K562 IC50
    1.16 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    [PMID: 26231079]
    K562 IC50
    13 μM
    Compound: Imatinib
    In vitro antiproliferative activity against human K562 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    In vitro antiproliferative activity against human K562 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    [PMID: 24681986]
    K562 IC50
    15.7 μM
    Compound: Imatinib
    Antiproliferative activity against imatinib-resistant human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against imatinib-resistant human K562 cells after 48 hrs by MTT assay
    [PMID: 26231079]
    K562 IC50
    250 nM
    Compound: Imatinib
    Inhibition of kinobead binding to ABL in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method
    Inhibition of kinobead binding to ABL in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method
    [PMID: 28280261]
    K562 IC50
    272 nM
    Compound: Imatinib
    Inhibition of kinobead binding to ARG in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method
    Inhibition of kinobead binding to ARG in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method
    [PMID: 28280261]
    K562 IC50
    3.43 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    [PMID: 29684708]
    K562 IC50
    310 nM
    Compound: Imatinib
    Cytotoxicity against human K562 cells assessed as decrease in cell proliferation after 72 hrs by XTT assay
    Cytotoxicity against human K562 cells assessed as decrease in cell proliferation after 72 hrs by XTT assay
    [PMID: 27214512]
    K562 IC50
    384.4 nM
    Compound: STI571, Gleevec
    Cytotoxicity against human BCR-ABL positive K562 cells after 48 to 72 hrs by MTT assay
    Cytotoxicity against human BCR-ABL positive K562 cells after 48 to 72 hrs by MTT assay
    [PMID: 22789429]
    K562 IC50
    4.12 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    [PMID: 26298495]
    K562 IC50
    4.12 μM
    Compound: Imatinib
    Antiproliferative activity against Bcr/Abl positive human K562 cells after 48 hrs by MTT method
    Antiproliferative activity against Bcr/Abl positive human K562 cells after 48 hrs by MTT method
    [PMID: 25464886]
    K562 IC50
    4.26 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
    [PMID: 34547714]
    K562 IC50
    4.26 μM
    Compound: STI-571
    Antiproliferative activity against human BCR/ABL positive K562 cells assessed as growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human BCR/ABL positive K562 cells assessed as growth inhibition measured after 48 hrs by MTT assay
    [PMID: 31185413]
    K562 IC50
    4.63 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells by MTS assay
    Antiproliferative activity against human K562 cells by MTS assay
    [PMID: 34015503]
    K562 IC50
    43 nM
    Compound: Imatinib
    Inhibition of kinobead binding to NQO2 in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method
    Inhibition of kinobead binding to NQO2 in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method
    [PMID: 28280261]
    K562 IC50
    5.4 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    [PMID: 21576023]
    K562 IC50
    7.38 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    [PMID: 28029512]
    K562 IC50
    76.2 nM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells incubated for 3 days by CCK8 assay
    Antiproliferative activity against human K562 cells incubated for 3 days by CCK8 assay
    [PMID: 32657579]
    K562 IC50
    82.9 nM
    Compound: Imatinib
    Cytotoxicity against human K562 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    [PMID: 34011155]
    K562 IC50
    87.32 μM
    Compound: Imatinib
    Cytotoxicity against human K562 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human K562 cells incubated for 48 hrs by MTT assay
    [PMID: 33938746]
    K562 IC50
    90 nM
    Compound: Imatinib
    Inhibition of kinobead binding to DDR1 in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method
    Inhibition of kinobead binding to DDR1 in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method
    [PMID: 28280261]
    K562/A02 IC50
    0.98 μM
    Compound: Imatinib
    Antiproliferative activity against human K562/A02 cells overexpressing P-gp by MTT assay
    Antiproliferative activity against human K562/A02 cells overexpressing P-gp by MTT assay
    [PMID: 33132117]
    K562/A02 IC50
    75.69 μM
    Compound: Imatinib
    Cytotoxicity against P-gp overexpressing human K562/A02 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against P-gp overexpressing human K562/A02 cells incubated for 48 hrs by MTT assay
    [PMID: 33938746]
    K562/Adr IC50
    13.47 μM
    Compound: Imatinib
    Antiproliferative activity against human Adriamycin-resistant K562/Adr cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human Adriamycin-resistant K562/Adr cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    [PMID: 35561654]
    K-562R IC50
    > 50 μM
    Compound: Imatinib
    Cytotoxicity in imatinib-resistant human K562R cells assessed as reduction cell viability incubated for 48 hrs by XTT assay
    Cytotoxicity in imatinib-resistant human K562R cells assessed as reduction cell viability incubated for 48 hrs by XTT assay
    [PMID: 29655981]
    K-562R IC50
    90 μM
    Compound: STI-571
    Antiproliferative activity against human K562R cells expressing BCR/ABL T315I mutant assessed as growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human K562R cells expressing BCR/ABL T315I mutant assessed as growth inhibition measured after 48 hrs by MTT assay
    [PMID: 31185413]
    K-562R IC50
    93.01 μM
    Compound: Imatinib
    Antiproliferative activity against human K-562R cells expressing Bcr-Abl T315I mutant assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human K-562R cells expressing Bcr-Abl T315I mutant assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    [PMID: 35561654]
    K-562R IC50
    98.82 μM
    Compound: IM